GlassScriptPhysician profile
Fred G Nagel
NPI 1922016674
$7,639.33
in general payments reported to CMS, 2019-2025
45 companies · $798 in 2025
The $798 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $1,266 · 2021: $1,199 · 2022: $937 · 2023: $1,073 · 2024: $1,074 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $850.48 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $723.80 | 2019-2024 | Jardiance |
| Pfizer INC. | $716.63 | 2019-2025 | |
| Abbvie INC. | $598.32 | 2021-2025 | |
| Lilly USA, LLC | $519.26 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $435.90 | 2022-2025 | |
| Novo Nordisk INC | $368.17 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $353.93 | 2019-2024 | Belsomra, Steglatro, Gardasil 9 |
| Astellas Pharma US INC | $320.78 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.53 | 2019-2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $197.43 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Glaxosmithkline, LLC. | $183.73 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $175.56 | 2019-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $165.47 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $161.56 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Nagel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.